{
    "nct_id": "NCT00408525",
    "title": "Efficacy of Donepezil in Normalizing Brain Activation Patterns in People Genetically at Risk for Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2018-02-01",
    "description_brief": "The purpose of the study is to examine patterns of brain activity in people who are at risk for memory problems (e.g., Alzheimer's disease or dementia)before and after the medication donepezil. Although genetic testing will be done, the results will not be shared with study participants.\n\nOnce the genetic testing is completed subjects may continue to the second phase of the study. During this time they will be asked to take the medication donepezil (which is approved by the FDA for the treatment of Alzheimer's disease).\n\nDonepezil is not FDA approved for healthy volunteers and is therefore considered investigational in this study.",
    "description_detailed": "HYPOTHESIS\n\n1. Cognitively intact individuals with normal brain morphology at genetic risk for developing Alzheimer's' Disease (AD) show alterations in brain activation patterns during tasks that require memory compared to similar individuals with lower risk for developing AD.\n2. Donepezil, a cholinesterase inhibitor, can normalize such brain activation patterns in subjects at risk for AD.\n\nSPECIFIC AIMS\n\n1. To replicate a recent study1, and compare brain activation in subjects genetically at risk for AD (carriers of the \u04544 allele of the apolipoprotein E gene (APOE)) with subjects at lower risk for AD (lacking the \u04544 allele) during tasks that require memory, via functional magnetic resonance imaging (fMRI).\n2. To determine if administration of a drug currently indicated in the treatment of AD, donepezil, can reverse fMRI brain activation patterns of at risk subjects to patterns similar to those of subjects at lower genetic risk for AD.",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "HEALTH_SERVICES_RESEARCH",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "donepezil"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial gives donepezil (an FDA\u2011approved Alzheimer\u2019s drug) to people at genetic risk and aims to examine whether donepezil \"normalizes brain activation patterns\" and affects memory/brain activity before/after medication. Donepezil is a reversible acetylcholinesterase inhibitor that increases synaptic acetylcholine and is used to provide symptomatic cognitive benefit in Alzheimer\u2019s disease rather than to remove amyloid or tau pathology; therefore the primary intent in this protocol (normalizing activation / improving cognitive-related brain signals) aligns with the definition of a cognitive enhancer. \ue200cite\ue202turn0search1\ue202turn0search0\ue201",
        "Act: Key extracted details \u2014 drug: donepezil (small\u2011molecule, reversible acetylcholinesterase inhibitor); trial purpose: evaluate brain activity/cognition before and after donepezil in people genetically at risk for Alzheimer's; note in the description donepezil is investigational for healthy volunteers in this study despite its FDA approval for symptomatic treatment of Alzheimer\u2019s dementia. Supporting sources: donepezil mechanism and symptomatic use (StatPearls / PubMed reviews). \ue200cite\ue202turn0search1\ue202turn0search6\ue201 Additional relevant literature showing donepezil modulates brain activation / functional connectivity in non\u2011demented or healthy participants (examples of prior studies measuring EEG/fMRI and resting\u2011state connectivity with donepezil). \ue200cite\ue202turn0search7\ue202turn0search9\ue201",
        "Reflect: Classification check \u2014 the four category definitions were: (1) disease\u2011targeted biologic (biologics targeting amyloid/tau), (2) disease\u2011targeted small molecule (small molecules targeting pathology), (3) cognitive enhancer (improves cognition without targeting core pathology), (4) neuropsychiatric symptom improvement. Donepezil is a small\u2011molecule cholinesterase inhibitor that provides symptomatic cognitive benefit rather than targeting amyloid/tau or altering disease course, so it best fits category 3: cognitive enhancer. Some reports discuss broader effects of donepezil on neural activity, but they do not establish disease\u2011modifying action; thus the cognitive enhancer classification is appropriate. \ue200cite\ue202turn0search1\ue202turn0search4\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The intervention is donepezil, a centrally acting, reversible acetylcholinesterase (AChE) inhibitor that increases synaptic acetylcholine and enhances cholinergic neurotransmission; the protocol\u2019s goal is symptomatic/cognitive modulation (normalizing brain activation), not targeting amyloid or tau pathology. \ue200cite\ue202turn0search0\ue202turn0search6\ue201",
        "Act: Key extracted details \u2014 drug: donepezil (small-molecule, reversible AChE inhibitor); trial purpose: examine whether donepezil normalizes brain activation and affects memory/brain activity in genetically at\u2011risk but not demented individuals. Prior fMRI/functional\u2011connectivity studies report donepezil-related changes in regional activation and resting\u2011state networks in AD, MCI and healthy participants, supporting that the drug acts via cholinergic/neurotransmitter modulation rather than disease modification. \ue200cite\ue202turn0search2\ue202turn0search3\ue202turn0search8\ue201",
        "Reflect: Classification check \u2014 CADRO category D (Neurotransmitter Receptors) is the best fit because the mechanism is to augment cholinergic neurotransmission (a neurotransmitter system). Although donepezil acts on the enzyme acetylcholinesterase rather than directly on a receptor, CADRO\u2019s Neurotransmitter/Receptor category covers interventions that modulate neurotransmitter systems (e.g., cholinergic agents) used as cognitive enhancers; the trial is symptomatic/cognitive in intent, not disease\u2011modifying. No evidence in the description that the trial targets amyloid, tau, ApoE/lipids, inflammation, proteostasis, vasculature, or multiple distinct CADRO mechanisms. \ue200cite\ue202turn0search0\ue202turn0search6\ue201",
        "Web search results (key sources used): StatPearls overview of donepezil mechanism and clinical use (reversible AChE inhibitor). \ue200cite\ue202turn0search0\ue201; StatPearls/CE summary of donepezil symptomatic use. \ue200cite\ue202turn0search1\ue201; Early pharmaco\u2011fMRI showing normalization of fusiform activation after donepezil in AD. \ue200cite\ue202turn0search2\ue201; Resting\u2011state functional connectivity changes with donepezil in healthy volunteers. \ue200cite\ue202turn0search3\ue201; fMRI evidence of cholinergic enhancement normalizing medial temporal activation in MCI. \ue200cite\ue202turn0search8\ue201"
    ]
}